The 2020 Cancer Statistics report estimates that 1,806,590 new cancer cases and 606,520 cancer deaths will occur in the United States. Cancer death rates declined continuously from 1991 to 2017, resulting in an overall decline of 29%, or about 2.9 million fewer cancer deaths. This progress is driven by long-term declines in death rates for the four leading cancers (lung, colorectal, breast, and prostate), although recent declines have slowed for female breast and colorectal cancers and halted for prostate cancer. In contrast, lung cancer mortality declined more rapidly, with a 2.2% drop in overall cancer mortality from 2016 to 2017. Despite this, lung cancer still caused more deaths than breast, prostate, colorectal, and brain cancers combined in 2017. Recent mortality declines for melanoma were dramatic, with annual declines of 7% in men and women aged 50-64 and 2-3% in those aged 20-49. Annual declines of 5-6% in individuals aged 65 and older are particularly notable, as rates in this age group were increasing prior to 2013. Long-term increases in liver cancer mortality have slowed in women and stabilized in men. The report highlights disparities in cancer outcomes by race and ethnicity, with non-Hispanic black men having higher cancer mortality rates than non-Hispanic white men. Geographic variation in cancer occurrence is also significant, with higher rates in states with higher smoking prevalence. Cancer survival has improved for many cancers, particularly for hematopoietic and lymphoid malignancies due to advances in treatment. However, survival rates vary by cancer type and age at diagnosis. The report also notes that cancer is the second leading cause of death in the United States, with lung cancer being the leading cause in many states and among certain populations. Despite progress, disparities in cancer outcomes persist, particularly for highly preventable cancers such as those of the cervix and lung. The report concludes that continued investment in cancer control interventions and research is essential to further reduce cancer mortality and improve outcomes.The 2020 Cancer Statistics report estimates that 1,806,590 new cancer cases and 606,520 cancer deaths will occur in the United States. Cancer death rates declined continuously from 1991 to 2017, resulting in an overall decline of 29%, or about 2.9 million fewer cancer deaths. This progress is driven by long-term declines in death rates for the four leading cancers (lung, colorectal, breast, and prostate), although recent declines have slowed for female breast and colorectal cancers and halted for prostate cancer. In contrast, lung cancer mortality declined more rapidly, with a 2.2% drop in overall cancer mortality from 2016 to 2017. Despite this, lung cancer still caused more deaths than breast, prostate, colorectal, and brain cancers combined in 2017. Recent mortality declines for melanoma were dramatic, with annual declines of 7% in men and women aged 50-64 and 2-3% in those aged 20-49. Annual declines of 5-6% in individuals aged 65 and older are particularly notable, as rates in this age group were increasing prior to 2013. Long-term increases in liver cancer mortality have slowed in women and stabilized in men. The report highlights disparities in cancer outcomes by race and ethnicity, with non-Hispanic black men having higher cancer mortality rates than non-Hispanic white men. Geographic variation in cancer occurrence is also significant, with higher rates in states with higher smoking prevalence. Cancer survival has improved for many cancers, particularly for hematopoietic and lymphoid malignancies due to advances in treatment. However, survival rates vary by cancer type and age at diagnosis. The report also notes that cancer is the second leading cause of death in the United States, with lung cancer being the leading cause in many states and among certain populations. Despite progress, disparities in cancer outcomes persist, particularly for highly preventable cancers such as those of the cervix and lung. The report concludes that continued investment in cancer control interventions and research is essential to further reduce cancer mortality and improve outcomes.